Compare LQDA & KBH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LQDA | KBH |
|---|---|---|
| Founded | 2004 | 1957 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Homebuilding |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.8B |
| IPO Year | 2020 | 1994 |
| Metric | LQDA | KBH |
|---|---|---|
| Price | $42.61 | $49.58 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 11 | 14 |
| Target Price | $41.00 | ★ $56.17 |
| AVG Volume (30 Days) | 930.9K | ★ 950.4K |
| Earning Date | 05-08-2026 | 03-24-2026 |
| Dividend Yield | N/A | ★ 1.91% |
| EPS Growth | ★ 51.81 | N/A |
| EPS | N/A | ★ 0.52 |
| Revenue | $158,320,000.00 | ★ $4,547,002,000.00 |
| Revenue This Year | $278.87 | N/A |
| Revenue Next Year | $57.13 | $9.23 |
| P/E Ratio | ★ N/A | $94.43 |
| Revenue Growth | ★ 1031.18 | N/A |
| 52 Week Low | $11.85 | $47.95 |
| 52 Week High | $46.67 | $68.71 |
| Indicator | LQDA | KBH |
|---|---|---|
| Relative Strength Index (RSI) | 65.57 | 39.80 |
| Support Level | $35.00 | $48.89 |
| Resistance Level | $46.67 | $65.46 |
| Average True Range (ATR) | 1.65 | 1.50 |
| MACD | 0.46 | -0.44 |
| Stochastic Oscillator | 92.74 | 17.66 |
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
KB Home is an American construction company that focuses on residential construction in the United States. The company builds single-family homes and communities across different geographical segments which include the West Coast which also derives the majority of the revenue, Southwest, Central, and Southeast. The company operates in several markets and focuses on first-time and move-up homebuyers. It also invests in land acquisition and development to support future building activities and is also engaged in financial services operations which includes providing mortgage banking services through its joint venture with a third party.